Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CCNH | P51946 | 1/20 | 0.34 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13904924 | 1.00 | ADORA2A (0.39) | ADORA2ACCNT1CCNKCDK7CDK9 | |
| SCHEMBL4135629 | 0.92 | ADORA2A (0.40) | ADORA2AADORA3ADORA2BADORA1P2RY2 | |
| SCHEMBL13904935 | 0.92 | ADORA2A (0.40) | ADORA2AADORA3ADORA2BADORA1P2RY2 | |
| SCHEMBL13906783 | 0.91 | ADORA2A (0.32) | ADORA2ACCNT1CCNKCDK7CDK9 | |
| SCHEMBL3951374 | 0.91 | ADORA2A (0.32) | ADORA2ACCNT1CCNKCDK7CDK9 | |
| SCHEMBL4137921 | 0.91 | ADORA2A (0.35) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL13905089 | 0.91 | ADORA2A (0.35) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL3957506 | 0.90 | ADORA2A (0.39) | ADORA2AADORA3ADORA2BADORA1P2RY2 | |
| SCHEMBL13906777 | 0.90 | ADORA2A (0.39) | ADORA2AADORA3ADORA2BADORA1P2RY2 | |
| SCHEMBL13904932 | 0.89 | CCNT1 (0.33) | CCNT1CCNKCDK7CDK9CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009029729-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-05 | — | — | WO | claimed |
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-03-05 | — | — | US | claimed |
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PNP, SLC29A1, SLC28A1 | ADORA2A 277/4885CCNT1 671/4885CCNK 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.